Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced non- small cell lung cancer (NSCLC)

Chaitanya R. Acharya,David S. Hsu,Bala S. Balakumaran,Kelli S. Walters,Vanja Vlahovic,Richard F. Riedel,Jennifer Garst,Phillip G. Febbo,Joseph R. Nevins,Anil Potti

Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced non- small cell lung cancer (NSCLC)

2016

Chaitanya R. Acharya
David S. Hsu
Bala S. Balakumaran
Kelli S. Walters
Vanja Vlahovic
Richard F. Riedel
Jennifer Garst
Phillip G. Febbo
Joseph R. Nevins
Anil Potti

7501 Background: Standard treatment for advanced non-small lung cancer (NSCLC) includes platinum-based therapy. Response is however suboptimal and unpredictable. Newer agents, such as pemetrexed, h...

Keywords:

non-small cell lung cancer (NSCLC)
Pathology
Pemetrexed
Cisplatin
Lung cancer
Internal medicine
Oncology
Pharmacogenomics
Standard treatment
Medicine
cisplatin resistant

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations